GenSight Biologics
Thomas Gidoin has been their Chief Financial Officer since June 2015. From 2012 to mid-2015, Thomas was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies on the Nasdaq Global Select Market in 2014.
From 2008 to 2011, he served in various positions at Ipsen S.A., including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young.
Thomas received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in France.
This person is not in any offices
GenSight Biologics
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.